Search results for "thiophene"

showing 10 items of 284 documents

The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors.

2013

Purpose: To describe the study design and baseline factors of the Heidelberg Retina Tomograph ancillary study within the EGPS. Furthermore, to examine the relationship between HRT optic disc topographic measurements and baseline demographic and ocular factors. Methods: Four hundred and eighty-nine ocular hypertensive participants were included. Each participant completed HRT imaging at least annually. The associations between HRT measurements and IOP, central corneal thickness (CCT), baseline photographic estimates of vertical CDR ratio (CDR), asymmetry between the two eyes in CDR ratio and baseline visual field indices were assessed using regression analysis. Results: Associations between …

MaleIntraocular pressureVisual acuitygenetic structuresOptic diskVisual AcuityOcular hypertensionGlaucomaOptic Nerve DiseasesMedicineHRT parameterCarbonic Anhydrase Inhibitorspattern standard deviationTomographySulfonamidesmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.anatomical_structureResearch DesignOptic nerveFemalemedicine.symptomHumanOptic discmedicine.medical_specialtyCarbonic Anhydrase Inhibitorscanning laser ophthalmoscopyOptic DiskVisual FieldThiophenesSulfonamideOphthalmoscopyTonometry OcularOptic Nerve DiseaseDouble-Blind MethodThiopheneOphthalmologymental disordersHumansIntraocular Pressurebusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmoscopyOphthalmologyOcular Hypertensionsense organsVisual Fieldsbusinesscentral corneal thickneActa ophthalmologica
researchProduct

Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolam…

2017

Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hyperten…

MaleIntraocular pressuregenetic structuresEye DiseasesPhysiologymedicine.medical_treatmentTimololGlaucomalcsh:Medicine030204 cardiovascular system & hematologyDexamethasone0302 clinical medicineGlaucoma surgeryMedicine and Health SciencesMedicineTrabeculectomyProspective Studieslcsh:ScienceSulfonamidesMultidisciplinaryPharmaceuticsDorzolamide/TimololOphthalmic ProceduresMiddle AgedDrug CombinationsTreatment OutcomeResearch DesignAnesthesiaTimololFemaleFluorouracilAnatomyAcetazolamidemedicine.drugResearch Articlemedicine.medical_specialtyLysis (Medicine)Clinical Research DesignSurgical and Invasive Medical ProceduresTrabeculectomyThiophenesResearch and Analysis Methods03 medical and health sciencesMusculoskeletal System ProceduresDorzolamideDrug TherapyOcular SystemOphthalmologyTissue RepairPreoperative CareHumansAntihypertensive AgentsIntraocular PressureAgedbusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesAcetazolamideOphthalmology030221 ophthalmology & optometryEyeslcsh:QOcular Hypertensionsense organsAdverse EventsOphthalmic SolutionsbusinessPhysiological ProcessesHeadPLoS ONE
researchProduct

Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.

2010

To evaluate the efficacy and tolerability of preservative-free eye drops (dorzolamide/timolol) in routine management of preservative-sensitive glaucoma patients.Data from 2,298 glaucoma patients requiring intraocular pressure (IOP) reduction and suffering from intolerance to benzalkonium chloride or active agents of previously used eye drops were valid for baseline and safety analysis in this prospective, open, noncomparative, multicenter, noninterventional study. Patients were treated with preservative-free dorzolamide/timolol eye drops for 12 weeks. Main efficacy endpoint was IOP reduction after 12 weeks of treatment. Two thousand forty-nine patients were considered for efficacy analysis.…

MaleIntraocular pressuregenetic structuresEye diseasemedicine.medical_treatmentAdministration TopicalGlaucomaTimololHyperemiaThiophenesDorzolamideMedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAntihypertensive AgentsIntraocular PressureAgedPharmacologySulfonamidesbusiness.industryPreservatives PharmaceuticalEye dropmedicine.diseaseeye diseasesOphthalmologyDrug CombinationsTreatment OutcomeTolerabilityAnesthesiaTimololFemalesense organsOphthalmic SolutionsbusinessBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal c…

2006

BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer. PATIENTS AND METHODS: Previously untreated patients with metastatic colorectal cancer received raltitrexed 2 mg/m(2) i.v. plus levofolinic acid and 5-fluorouracil according to the De Gramont' schedule given every 2 weeks as first-line chemotherapy. Patients were re-evaluated after six cycles and chemotherapy was continued up to tolerance or disease progression. RESULTS: Seventy patients aged >/=65 years were accrued from 11 centers between September 2001 and …

MaleOncologymedicine.medical_specialtyColorectal cancerfolinic acidmedicine.medical_treatmentLeucovorincolorectal cancerThiophenesAdenocarcinomaNeutropeniaGastroenterologyDrug Administration ScheduleFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans5-fluorouracilNeoplasm MetastasisAgedAged 80 and overChemotherapybusiness.industryraltitrexedHematologymedicine.diseaseRegimenOncologyFluorouracilmetastaseQuinazolinesFemaleFluorouracilNeoplasm Recurrence LocalColorectal NeoplasmsbusinessRaltitrexedmedicine.drugAnnals of Oncology
researchProduct

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) comp…

2019

Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronchi by adressing both muscarinic acetylcholine receptors and β2-adrenoceptor. However, the anti-inflammatory effects of the AZD8999 monotherapy or in combination with corticosteroids are unknown. This study investigates the anti-inflammatory effects of AZD8999 in monotherapy and combined with fluticasone propionate in neutrophils from healthy and chronic obstructive pulmonary disease (COPD) patients. Peripheral blood neutrophils from healthy and C…

MalePulmonologyNeutrophilsPhysiologyAnti-Inflammatory AgentsPharmacologyPathology and Laboratory MedicineBiochemistryPulmonary Disease Chronic ObstructiveWhite Blood CellsGlucocorticoid receptorAnimal CellsMuscarinic acetylcholine receptorMedicine and Health SciencesPost-Translational ModificationPhosphorylationReceptorImmune ResponseMultidisciplinaryPharmaceuticsQRDrug SynergismMiddle AgedReceptors MuscarinicHealthy VolunteersBody FluidsChemistryBloodPhysical SciencesQuinolinesMedicineDrug Therapy CombinationFemalemedicine.symptomCellular TypesAnatomymedicine.drugResearch ArticleSignal TransductionAgonistTransmembrane Receptorsmedicine.drug_classp38 mitogen-activated protein kinasesChronic Obstructive Pulmonary DiseaseImmune CellsScienceImmunologyInflammationMuscarinic AntagonistsThiophenesFluticasone propionateSigns and SymptomsDrug TherapyCyclohexanesDiagnostic MedicinemedicineHumansAdrenergic beta-2 Receptor AgonistsAgedInflammationBlood CellsDose-Response Relationship Drugbusiness.industryAntagonistChemical CompoundsBiology and Life SciencesProteinsCell BiologyAcetylcholine ReceptorsFluticasoneMuscarinic Acetylcholine ReceptorsReceptors Adrenergic beta-2PropionatesbusinessReceptor Antagonist TherapyPLoS ONE
researchProduct

The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study

2017

This study evaluated the effect of ≥6 months of transdermal rotigotine on non-motor and motor symptoms of patients with advanced Parkinson's disease.The study was conducted in Spain between September 2011 and December 2012 (ClinicalTrials.gov: NCT01504529). The primary efficacy variable was the change from baseline in non-motor symptoms, as assessed by changes in Parkinson's Disease Non-Motor Symptoms Questionnaire total scores at 6 months. Secondary endpoints included the assessment of motor symptoms by Unified Parkinson's Disease Rating Scale III scores.Data from 378 patients (mean age: 70.2 years; 56.9% male) with Parkinson's disease receiving rotigotine from were collected. Mean disease…

MaleSleep Wake Disordersmedicine.medical_specialtyParkinson's diseaseTetrahydronaphthalenesThiophenesDiseaseAdministration CutaneousMotor symptoms03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesProduct Surveillance PostmarketingmedicineHumans030212 general & internal medicineAgedRetrospective StudiesTransdermalAged 80 and overbusiness.industryGeneral NeuroscienceParkinson DiseaseRotigotineGeneral MedicineUrination Disordersmedicine.diseaseClinical PracticeTreatment OutcomeSpainDopamine AgonistsPhysical therapyNon motorFemaleObservational studyCognition Disordersbusiness030217 neurology & neurosurgerymedicine.drugInternational Journal of Neuroscience
researchProduct

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST tria…

2010

Introduction: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ)12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients…

MaleSystolic hypertensionOffice VisitsPharmacologySeverity of Illness Indexlaw.inventionHydrochlorothiazideRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerPharmacology (medical)DiureticsImidazolesGeneral MedicineBlood Pressure Monitoring AmbulatoryAntihypertensive AgentLosartanHydrochlorothiazideTreatment OutcomeAcrylatesHypertensionCardiologyDrug Therapy CombinationFemaleDrug MonitoringHumanmedicine.drugmedicine.medical_specialtyAmbulatory blood pressureSystoleLosartan/hydrochlorothiazideThiopheneselderly patientselderlyLosartanStatistics NonparametricDouble-Blind MethodThiopheneInternal medicinemedicineDiureticHumansImidazoleAntihypertensive AgentsAgedAnalysis of Variancebusiness.industryeprosartanEprosartanmedicine.diseaseambulatory blood pressure monitoringAcrylateBlood pressureOffice VisitbusinessAngiotensin II Type 1 Receptor BlockersAdvances in therapy
researchProduct

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes

2013

Item does not contain fulltext BACKGROUND: Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration--before or after coronary angiography--is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. METHODS: We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to recei…

Malemedicine.medical_specialtyAcute coronary syndromePrasugrelmedicine.medical_treatmentPremedicationMyocardial InfarctionHemorrhageThiophenesCoronary AngiographyPiperazinesPercutaneous Coronary InterventionDouble-Blind MethodInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassAgedCardiovascular diseases [NCEBP 14]business.industryMedicine (all)Hazard ratioAcute Coronary Syndrome; Aged; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Coronary Angiography; Premedication; Medicine (all)Percutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedta3121medicine.diseaseConventional PCICardiologyPurinergic P2Y Receptor AntagonistsFemalebusinessPrasugrel HydrochlorideTIMImedicine.drug
researchProduct

Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.

2014

Abstract Aims We evaluated the impact of baseline comorbidities on the effectiveness of duloxetine and anticonvulsants (pregabalin/gabapentin) in patients with painful diabetic neuropathy in clinical care. Methods Outcomes from a 6-month, observational study with 2575 patients initiating/switching DPNP treatment were analyzed post-hoc. Propensity scoring was used to adjust for baseline factors influencing treatment choice in 1523 patients receiving duloxetine or anticonvulsants. Analysis of covariance models with fixed effects for baseline pain, treatment, propensity score, baseline characteristics or comorbidities, and their interaction with treatment were used to estimate LSmean effects o…

Malemedicine.medical_specialtyGabapentinCyclohexanecarboxylic AcidsEndocrinology Diabetes and MetabolismPregabalinPregabalinComorbidityThiophenesDuloxetine Hydrochloridechemistry.chemical_compoundEndocrinologyDiabetic NeuropathiesInternal MedicinemedicineDuloxetineHumansPain ManagementBrief Pain InventoryAminesDepression (differential diagnoses)gamma-Aminobutyric AcidAgedPain MeasurementRetrospective StudiesAnalgesicsbusiness.industryChronic painMiddle Agedmedicine.diseasePrognosisTreatment OutcomechemistryJoint painPropensity score matchingPhysical therapyAnticonvulsantsFemalemedicine.symptomGabapentinbusinessmedicine.drugJournal of diabetes and its complications
researchProduct